DE69724009D1 - PYRROLE ALS sPLA2 INHIBITOREN - Google Patents

PYRROLE ALS sPLA2 INHIBITOREN

Info

Publication number
DE69724009D1
DE69724009D1 DE69724009T DE69724009T DE69724009D1 DE 69724009 D1 DE69724009 D1 DE 69724009D1 DE 69724009 T DE69724009 T DE 69724009T DE 69724009 T DE69724009 T DE 69724009T DE 69724009 D1 DE69724009 D1 DE 69724009D1
Authority
DE
Germany
Prior art keywords
pyrrole
spla2 inhibitors
spla2
inhibitors
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69724009T
Other languages
English (en)
Other versions
DE69724009T2 (de
Inventor
J Bach
D Dillard
E Draheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69724009D1 publication Critical patent/DE69724009D1/de
Application granted granted Critical
Publication of DE69724009T2 publication Critical patent/DE69724009T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE69724009T 1996-12-10 1997-12-09 PYRROLE ALS sPLA2 INHIBITOREN Expired - Fee Related DE69724009T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3329096P 1996-12-10 1996-12-10
US33290P 1996-12-10
PCT/US1997/022625 WO1998025609A1 (en) 1996-12-10 1997-12-09 PYRROLES AS sPLA2 INHIBITORS

Publications (2)

Publication Number Publication Date
DE69724009D1 true DE69724009D1 (de) 2003-09-11
DE69724009T2 DE69724009T2 (de) 2004-06-09

Family

ID=21869573

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69724009T Expired - Fee Related DE69724009T2 (de) 1996-12-10 1997-12-09 PYRROLE ALS sPLA2 INHIBITOREN

Country Status (13)

Country Link
US (1) US5919774A (de)
EP (1) EP0983064B1 (de)
JP (1) JP2001505915A (de)
KR (1) KR20000069377A (de)
AT (1) ATE246501T1 (de)
AU (1) AU5598398A (de)
BR (1) BR9714002A (de)
CA (1) CA2274571A1 (de)
DE (1) DE69724009T2 (de)
ES (1) ES2203828T3 (de)
HU (1) HUP0000167A3 (de)
IL (1) IL130338A0 (de)
WO (1) WO1998025609A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042307A (ko) 1998-03-31 2001-05-25 시오노 요시히코 피롤로[1,2-ａ]피라진 ｓＰＬＡ2 억제제
EP1085021A4 (de) 1998-05-21 2003-01-08 Shionogi & Co PYRROLO[1,2-B]PYRIDAZIN-DERIVATE MIT sPLA 2? HEMMENDEM EFFEKT
US6325991B1 (en) 1998-08-24 2001-12-04 Susan E. Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
ATE329619T1 (de) 1998-10-14 2006-07-15 Shionogi & Co Spla2-inhibitoren zur behandlung von ischämischen reperfusionsschäden
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
JP4636522B2 (ja) 1999-08-02 2011-02-23 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有する三環式化合物
WO2001014378A1 (fr) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
AU2001267823A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
WO2002012249A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
TWI314457B (de) 2001-03-19 2009-09-11 Shionogi & Co
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
EP2322501B1 (de) 2002-01-08 2015-08-05 Paratek Pharmaceuticals, Inc. 4-Dedimethylamin-Tetracyclinverbindungen
KR101093842B1 (ko) 2002-03-08 2011-12-13 파라테크 파마슈티컬스, 인크. 아미노-메틸 치환된 테트라시클린 화합물
CN1653037A (zh) 2002-03-21 2005-08-10 帕拉特克药品公司 取代的四环素化合物
KR101089429B1 (ko) 2002-07-12 2011-12-07 파라테크 파마슈티컬스, 인크. 3, 10, 및 12ａ 치환된 테트라시클린 화합물
EA201001081A1 (ru) 2003-07-09 2011-02-28 Пэрэтек Фамэсьютикэлс, Инк. Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
EP1656341A1 (de) 2003-07-09 2006-05-17 Paratek Pharmaceuticals, Inc. Prodrugs von 9-aminomethyltetracyclinverbindungen
EP1716101A1 (de) * 2004-01-15 2006-11-02 Paratek Pharmaceuticals, Inc. Derivate von tetracyclinverbindungen mit aromatischem a-ring
JP2008518035A (ja) 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド 置換テトラサイクリン化合物
EP1805134B1 (de) 2004-10-25 2012-06-20 Paratek Pharmaceuticals, Inc. 4-aminotetracycline und verfahren zu ihrer verwendung
AU2006272698B2 (en) * 2005-07-21 2012-11-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
CA2673466C (en) 2006-12-21 2016-06-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
LT2120963T (lt) * 2006-12-21 2019-01-10 Paratek Pharmaceuticals, Inc. Pakeistieji tetraciklino junginiai uždegiminių odos ligų gydymui
AU2008246119A1 (en) * 2007-04-27 2008-11-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
EA201070233A1 (ru) * 2007-07-06 2010-08-30 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
TWI585071B (zh) 2008-05-23 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
ES2430254T3 (es) 2008-08-08 2013-11-19 Tetraphase Pharmaceuticals, Inc. Compuestos de tetraciclina sustituidos con c7-fluoro
CA2761241C (en) 2009-05-08 2018-02-27 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
CN105622496B (zh) 2009-08-28 2019-03-05 四相制药公司 四环素类化合物
WO2011123536A1 (en) 2010-03-31 2011-10-06 Tetraphase Pharmaceuticals, Inc. Polycyclic tetracycline compounds
BR112015004523B1 (pt) 2012-08-31 2020-08-04 Tetraphase Pharmaceuticals, Inc Compostos de tetraciclina, composições farmacêuticas e seus usos
US10961190B2 (en) 2016-10-19 2021-03-30 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline
WO2020097450A1 (en) 2018-11-09 2020-05-14 Tetraphase Pharmaceuticals, Inc. Polymorphic forms of a compound and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1083044A (en) * 1976-05-04 1980-08-05 Stewart Wong Antiarthritic potentiation
DE3629929A1 (de) * 1986-09-03 1988-03-10 Thomae Gmbh Dr K Neue sulfonamido-aethylverbindungen, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0300688A1 (de) * 1987-07-21 1989-01-25 FISONS plc Pyrrol-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammenstellungen, die sie enthalten
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
CN1067054C (zh) * 1994-04-01 2001-06-13 伊莱利利公司 1H-吲哚-3-乙醛酰胺sPLA2抑制剂

Also Published As

Publication number Publication date
ES2203828T3 (es) 2004-04-16
EP0983064A4 (de) 2001-01-31
BR9714002A (pt) 2000-05-16
WO1998025609A1 (en) 1998-06-18
CA2274571A1 (en) 1998-06-18
EP0983064A1 (de) 2000-03-08
KR20000069377A (ko) 2000-11-25
US5919774A (en) 1999-07-06
ATE246501T1 (de) 2003-08-15
IL130338A0 (en) 2000-06-01
AU5598398A (en) 1998-07-03
HUP0000167A3 (en) 2001-01-29
EP0983064B1 (de) 2003-08-06
JP2001505915A (ja) 2001-05-08
HUP0000167A2 (hu) 2000-09-28
DE69724009T2 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
DE69724009D1 (de) PYRROLE ALS sPLA2 INHIBITOREN
MY112897A (en) Ih-indole-3-glyoxylamide spla2 inhibitors
BR9508298A (pt) Inibidores de indolizina de spla2
MX9804751A (es) Naftil acetamidas como inhibidores de la spla2.
ATE326963T1 (de) Indolverbindungen als spla2 inhibitoren
ATE234850T1 (de) Phenylglyoxamide als spla2-inhibitoren
ATE247119T1 (de) Substituierte pyrroloindole
ATE350367T1 (de) Spla2 inhibitoren
WO2002012249A3 (en) Substituted pyrrole compounds and their use as spla2 inhibitors
AU7053700A (en) Novel spla2 inhibitors
DE60126831D1 (de) Benz(g)indole und deren verwendung als spla2 inhibitoren

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee